艾尔巴韦/格拉瑞韦联合索磷布韦治疗基因3型丙型肝炎病毒感染合并代偿期肝硬化:一项随机试验
C-ISLE研究是一项2期随机开放标签试验,评估艾尔巴韦/格拉瑞韦联合索磷布韦±利巴韦林治疗基因3型丙型肝炎病毒感染合并代偿期肝硬化患者的疗效与安全性。初治患者接受8周联合利巴韦林或12周无利巴韦林方案,经治患者接受12周±利巴韦林或16周无利巴韦林方案。初治患者SVR12为91%(21/23)和96%(23/24),经治患者为94%(17/18)、100%(17/17)和94%(17/18)。结论支持初治和聚乙二醇干扰素/利巴韦林经治患者使用12周无利巴韦林方案。
要点
- 初治患者8周联合利巴韦林SVR12为91%(21/23),12周无利巴韦林为96%(23/24)。
- 经治患者12周联合利巴韦林SVR12为94%(17/18),无利巴韦林为100%(17/17),16周无利巴韦林为94%(17/18)。
- SVR12不受耐药相关替换存在的影响,超过12周的治疗并非必需。
核心结论
- 本研究数据支持初治和聚乙二醇干扰素/利巴韦林经治的基因3型丙型肝炎病毒感染合并肝硬化患者使用艾尔巴韦/格拉瑞韦联合索磷布韦治疗12周且不加用利巴韦林。
研究设计与样本
- C-ISLE研究为2期随机开放标签研究,纳入基因3型丙型肝炎病毒感染合并代偿期肝硬化参与者。
- 初治参与者接受艾尔巴韦/格拉瑞韦+索磷布韦+利巴韦林8周或艾尔巴韦/格拉瑞韦+索磷布韦12周。
- 聚乙二醇干扰素/利巴韦林经治参与者接受艾尔巴韦/格拉瑞韦+索磷布韦±利巴韦林12周或艾尔巴韦/格拉瑞韦+索磷布韦16周。
主要发现
- 初治参与者中,8周联合利巴韦林组SVR12为91%(21/23),12周无利巴韦林组为96%(23/24)。
- 经治参与者中,12周联合利巴韦林组SVR12为94%(17/18),12周无利巴韦林组为100%(17/17),16周无利巴韦林组为94%(17/18)。
- 5例参与者未达到SVR:2例复发(均在8周组),1例因呕吐/蜂窝织炎停药(16周组),2例停药(撤回知情同意/失访)。
- SVR12不受耐药相关替换存在的影响。
- 胰岛素抵抗无一致变化,5例参与者报告严重不良事件(肺炎、胸痛、阿片类药物过量、蜂窝织炎、肌酐降低)。
关键数值与推荐
- 主要终点为治疗结束后12周HCV RNA <15 IU/mL(持续病毒学应答[SVR12])。
临床怎么用
- 作者结论认为,本研究数据支持初治和聚乙二醇干扰素/利巴韦林经治的基因3型丙型肝炎病毒感染合并肝硬化患者使用艾尔巴韦/格拉瑞韦联合索磷布韦治疗12周且不加用利巴韦林。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Many direct-acting antiviral regimens have reduced activity in people with hepatitis C virus (HCV) genotype (GT) 3 infection and cirrhosis. The C-ISLE study assessed the efficacy and safety of elbasvir/grazoprevir (EBR/GZR) plus sofosbuvir (SOF) with and without ribavirin (RBV) in compensated cirrhotic participants with GT3 infection. This was a phase 2, randomized, open-label study. Treatment-naive participants received EBR/GZR + SOF + RBV for 8 weeks or EBR/GZR + SOF for 12 weeks, and peginterferon/RBV treatment-experienced participants received EBR/GZR + SOF ± RBV for 12 weeks or EBR/GZR + SOF for 16 weeks. The primary endpoint was HCV RNA <15 IU/mL 12 weeks after the end of treatment (sustained virologic response at 12 weeks [SVR12]). Among treatment-naive participants, SVR12 was 91% (21/23) in those treated with RBV for 8 weeks and 96% (23/24) in those treated for 12 weeks. Among treatment-experienced participants, SVR12 was 94% (17/18) and 100% (17/17) in the 12-week arm, with and without RBV, respectively, and 94% (17/18) in the 16-week arm. Five participants failed to achieve SVR: 2 relapsed (both in the 8-week arm), 1 discontinued due to vomiting/cellulitis (16-week arm), and 2 discontinued (consent withdrawn/lost to follow-up). SVR12 was not affected by the presence of resistance-associated substitutions (RASs). There was no consistent change in insulin resistance, and 5 participants reported serious adverse events (pneumonia, chest pain, opiate overdose, cellulitis, decreased creatinine). High efficacy was demonstrated in participants with HCV GT3 infection and cirrhosis. Treatment beyond 12 weeks was not required, and efficacy was maintained regardless of baseline RASs. CONCLUSION: Data from this study support the use of EBR/GZR plus SOF for 12 weeks without RBV for treatment-naive and peginterferon/RBV-experienced people with GT3 infection and cirrhosis (ClinicalTrials.gov NCT02601573). (Hepatology 2018;67:2113-2126).
引用
- Foster GR, Agarwal K, Cramp ME, et al. Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial. Hepatology. 2018. PMID: 29473975. doi:10.1002/hep.29852
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。